Navigation Links
Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months
Date:10/18/2007

(UNAUDITED)

Three Months Ended Nine Months Ended

9/30/2007 9/30/2006 9/30/2007 9/30/2006

Net Revenue $5,619,536 $5,135,796 $16,636,272 $15,130,476

Cost of Goods Sold 1,617,581 1,386,254 4,622,269 4,096,931

Selling, General and

Administrative

Expenses 1,670,671 1,588,947 4,871,222 4,705,940

Research and Development

Expenses 798,464 762,623 2,374,319 2,197,966

Interest Income, Net (39,622) (8,126) (73,440) (122)

Other Income, Net(1) (61,416) (39,488) (251,748) (205,539)

Income Before Income

Taxes 1,633,858 1,445,586 5,093,650 4,335,300

Provision for Income

Taxes 487,953 288,668 1,495,120 994,009

Net Income $1,145,905 $1,156,918 $3,598,530 $3,341,291

Basic Earnings Per

Share(2) $0.85 $0.86 $2.68 $2.48

Average Number of Common

Shares Outstanding During

Each Period - Basic 1,343,036 1,345,535 1,343,897 1,345,150

Diluted Earnings Per

Share(2) $0.84 $0.85 $2.63 $2.45

Average Number of Common

Shares Outstanding During

Each Period - Diluted 1,372,145 1,372,798 1,376,505 1,372,341

See Notes to Results of Operations and Results of Operations - As Adjusted.

Results of Operations - As Adjusted

Wyeth has prepared the following presentation of its results of operations for the three and nine months ended September 30, 2007 and 2006, adjusted where noted below, to exclude productivity initiatives charges and the 2006 income tax adjustment, which are considered certain significant items during the 2007 a
'/>"/>

SOURCE Wyeth
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Wyeth Launches Vaccine for Pneumococcal Disease in India
2. Wyeth Embroiled in a Lawsuit over its Hormone Replacement Therapy
3. Wyeth Pharma Wins Law Suit
4. Verdict Against Wyeth Pharma in Prempro Case
5. FDA Approves Wyeths Oral Contraceptive Lybrel
6. Autopsy reports could be valuable and informative
7. China reports declining number of SARS Cases
8. Russia Reports First SARS Case
9. Research reports that c-section deliveries are rising
10. Jharkhand reports 13,000 Malaria cases
11. Uganda Reports Failure To Contain Sleeping Sickness

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...HINGTON, Nov. 9 The Churchill Ce...ward For Leadership to J.W. "Bill" Marriott for hi...gh progressive free market practices and fostering...Mr. Marriott will receive his award at a ceremony ...on D.C. Four Seasons Hotel. ,, "This is a test...
(Date:11/9/2009)... ANGELES, Nov. 9 Tracy Anderson, t...nd Kate Hudson, will be hosting two events at her ...Finally sharing her long awaited Nutritional Meal ...ng her TA Baby Food Cleanse and Lifestyle Menu. S...porates her entire method of cardio and muscle str...
(Date:11/9/2009)...y be left atrial enlargement, study finds , ...s a major risk factor for left atrial enlargement,...stroke and death, a new study shows. , Atrial f...(an irregular heart rhythm or heartbeat). , Re...ed 25 to 74, in Germany who were followed for 10 y...
(Date:11/9/2009)... Studying Genetic Variance Across ... of Genes , (Vocus) Novem...tries can be extraordinarily valuable when analyzi...-center genetics study that scanned the genomes ...regional differences, Drs. Chao Tian and Michael F...
(Date:11/9/2009)...ly due to fact that both eye conditions are age-re...9 (HealthDay News) -- Cataract surgery doesn,t app...r degeneration (AMD), according to a new study tha... vision loss worsens the other. , "Because both...uals with cataract also have AMD," wrote Li Ming D...
Breaking Medicine News(10 mins):Health News:J.W. 'Bill' Marriott to Receive Churchill Centre Award For Leadership 2Health News:Celebrity Trainer Tracy Anderson Sharing Her Fitness and Diet Secrets This Week 2Health News:News from the November/December Issue of Molecular Medicine 2Health News:Cataract Surgery Doesn't Worsen Macular Degeneration: Study 2
...eam of doctors from different specialties, recentl...roach can benefit cancer patients. Dr. Peter Costa... found a rare and often fatal tumor in Angela Carr...gnosed in 2002. This type of cancer makes up about...
...ry year, more than 5 million people go to the Emer... for 20 to 30 minutes. Most receive an ECG and oth...a heart attack or other serious heart problems. Ho...in. Researchers suggest// that about 2 percent of ...
...riasis patients who have been long-awaiting new op...ood and Drug Administration's approval of the new ...immune cells to control hard-to-treat psoriasis. P...that are currently available for psoriasis range f...
...ple have been concerned, for many decades now, abo...e smile. But tooth discolouration is a persistent ...les in food and drink. Back in the Middle Ages, pe...red many easy and ingenuous ways of maintaining te...
...ecent study has has shown that oxygen, apart from ... Prior studies have shown that oxygen plays an imp.... In fact, studies have shown treatment in a hyper...ity. The researchers of the new have now suggested...
...nking milk has always been associated with good he...o drink milk to grow up healthy. However, a recent... well established fact(or is it still?). A study i...ein and the national rate of heart disease and ins...
Other Medicine News:Health News:New and unique treatment for Psoriasis patients 2
(Date:11/9/2009)..., AUSTIN, Texas, Nov. 9 Celli...rs, is collaborating with Tissue Genesis, Inc. to ... derived adult stem cells. SpineSmith acquired th...se (fat) tissue derived stem cell technology in No...this new exclusive agreement allows Celling Techno...
(Date:11/9/2009)..., ST. LOUIS, Nov. 9, 2009 /PRNewswire-FirstCa...nc (NYSE: PFE ) today announced that they have en...izer,s Chesterfield Village Research Center locate...eement, Monsanto will acquire the property from Pf...izer will continue to have operations at Chesterfi...
(Date:11/9/2009)..., PISCATAWAY, N.J., Nov. 9 /PRNewswire-FirstC...ard: MLSS), the recognized leader in computer-cont...t it will be showcasing its patented, award-winnin...ystem) at the Madow Group,s 15th year of TBSE tit... place at the Las Vegas Hilton. ,, The STA S...
Breaking Medicine Technology:Celling Technologies Signs Exclusive Agreement to Research and Develop Adipose Tissue Stem Cell Technology in Regenerative Medicine Institutes 2Celling Technologies Signs Exclusive Agreement to Research and Develop Adipose Tissue Stem Cell Technology in Regenerative Medicine Institutes 3Monsanto to Purchase Chesterfield Village Research Center From Pfizer 2Monsanto to Purchase Chesterfield Village Research Center From Pfizer 3Milestone Scientific to Exhibit at the 15th Anniversary of TBSE (The Best Seminar Ever) in Las Vegas 2Hard to Treat Diseases Inc 28HTDS 29 Reports on Ribavirin Research as Potential Treatment for MS 52558 1Hard to Treat Diseases Inc 28HTDS 29 Reports on Ribavirin Research as Potential Treatment for MS 52558 2Hard to Treat Diseases Inc 28HTDS 29 Reports on Ribavirin Research as Potential Treatment for MS 52558 3Video of EpiDerm Skin Irritation Test 28SIT 29 Method Now Available 13170 1Video of EpiDerm Skin Irritation Test 28SIT 29 Method Now Available 13170 2Twinlabs 28R 29 Mobile Beach Bash Heats Up After a Successful Kick Off of the 2009 RateYourAbs com Contest 52549 1Twinlabs 28R 29 Mobile Beach Bash Heats Up After a Successful Kick Off of the 2009 RateYourAbs com Contest 52549 2
....Y.--(BUSINESS WIRE)--Jun 18, 2007 - Advanced Vira...iopharmaceutical,company, announced today that pre...ological study show topical treatment with AVR118,...ammation and,redness associated with surgical inci...open label dermatological study is evaluating the,...
...an 70 abstracts highlight VELCADE efficacy in broa...-, CAMBRIDGE, Mass., June 19, 2007 /PRNewswire-Fir...announced that data for,VELCADE, the market leadin...or patients with previously treated multiple myelo...ional Myeloma,Workshop (IMW) in Kos, Greece, June ...
Other Medicine Technology:Advanced Viral Research Corp. Announces Positive Preliminary,Findings from Ongoing Phase II Dermatological Study 2Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 2Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 3Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 4Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 5Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 6Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 7Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 8
DeepLight Glaucoma Treatment System
Verity Adx Pacemaker
Regency Pacemaker
Identity® Adx Pacemaker
Medicine Products: